Clinical Trials

The purpose of this study is to evaluate the feasibility and acceptability of the AKI in Care Transitions pilot and iteratively refine the intervention.  Generate preliminary estimates of the ACT intervention on clinical and patient-reported outcomes.

The purpose of this study is to facilitate quality improvement and description of treatment with this novel dialysis device dedicated to the treatment of infants with AKI or fluid overload.

The investigators are doing this research to find out if more careful assessment and elimination of potential risk factors of acute kidney injury (AKI) during the subject's perioperative period will reduce their chance of kidney damage and kidney damage related problems.

The purpose of this study is to determine if, in critically ill patients with severe acute kidney injury, an earlier start of renal replacement therapy compared to standard treatment will lead to improved survival and recovery of kidney function.

The purpose of this post-market surveillance study is to capture data on children who undergo CRRT using the Carpediem™ system. Participating clinicians will manage subjects in accordance to their local standard of care practices and decisions on initiating, modifying or discontinuing CRRT are up to the local investigative team's prescription. 

The study aims are to evaluate the safety and effectiveness of OCE-205 at various doses. Participants will receive treatment by intravenous infusion and will continue this treatment until participants meet primary endpoint or any discontinuation criteria.  OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites.

The purpose of this study is to investigate the effect of using high versus low bicarbonate containing replacement fluid in patients with metabolic acidosis receiving continuous renal replacement therapy (CRRT) with veno-venous hemofiltration (CVVH) for acute kidney injury (AKI) on in-hospital mortality.

The purpose of this study is to assess safety/effectiveness for continuous terlipressin infusion adult subjects on the liver transplant wait list with Hepatorenal syndrome- Acute Kidney Injury (HRS-AKI).

The purpose of this study is to see if Nephrology participation in the care of patients undergoing CABG (coronary artery bipass grafting) could reduce the incidence of acute kidney injury through correction of modifiable risk factors, early detection and interventions post-operatively.

The objective of this study is to evaluate the feasibility of alternative Net Ultrafiltration (UFNET) rate strategies among critically ill adults with acute kidney injury (AKI) and treated with Continuous Kidney Replacement Therapy (CKRT).

The purpose of this study is to evaluate the safety and effectiveness of OCE-205 at various doses.

OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites.  

The purpose of this study is to to collect urine samples to validate the NEPHROCLEARTM CCL14 Test in intensive care unit (ICU) patients with moderate to severe (Stage 2 or 3) acute kidney injury (AKI) as an aid in the risk assessment for developing persistent severe AKI (Stage 3 AKI lasting > 72 hours) within 48 hours of patient assessment.

The purpose of this study is to develop real-time kidney behavior monitoring and enable near-immediate (within minutes) recognition of kidney distress (versus kidney damage) in hospitalized patients.

The purpose of this study is to assess the ability of education and outpatient kidney care follow-up to improve patient knowledge about acute kidney injury (AKI).

The purpose of this study is to evaluate the effect of RBT-1 on preconditioning response biomarkers in subjects who are at risk for acute kidney injury (AKI) following cardiac surgery.

The purpose of this study is to evaluate the baseline presence of plasma levels of biomarkers of renal injury and changes in these biomarkers during the course of in-hospital intravenous diuretic therapy can predict when threshold values that would indicate a clinically significant change in renal function that would warrant a change in diuretic therapy to occur.

This parallel-group, randomized, placebo-controlled study will examine the incidence and severity of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) stage III/IV following an i.v. injection of iso-osmolar iodinated contrast material iodixanol (Visipaque™ Injection 320 mgI/mL), as compared with patients who received saline and underwent a non-enhanced CT (NECT) and duplex ultrasound (US) during their scheduled post-EVAR surveillance imaging.

The purpose of this study is to develop a better blood test to diagnose early kidney injury in type 1 diabetes.

The purpose of this study is to develop educational materials that will help patients and clinicians talk about treatment options for patients with advanced kidney disease.

The purpose of this study of obinutuzumab administered as intravenous (IV) infusion in adults with end stage renal disease is to assess the safety and tolerability of the regimen at week 24 of the desensitization phase and at week 28 post kidney transplantation. All participants will be monitored for a minimum of 12 months following the last obinutuzumab infusion.

The overall objective of this project is to determine the feasibility of implementing a superspecialist consult model between Mayo Clinic and UMMC in the field of OB nephrology in 20 participants who are ≥ 18 years of age. 

The primary purpose of this study is to examine 1-year survival and rate of secondary infections in COVID-19 patients with and without acute kidney injury (AKI).

The purpose of this study is to identify the clinical characteristics, the management and the outcomes of acute kidney injury (AKI) in patients with cirrhosis worldwide. Additionally, to establish the severity of AKI across different regions, to identify precipitants of AKI across different centers, to identify the phenotypes of AKI across different centers, to evaluate differences in the management of AKI across different centers and their impact on clinical outcomes, and to assess outcomes of acute kidney injury (resolution of AKI, in-hospital mortality, 28-day mortality, 90-day mortality).